Antibacterial compositions for drug administration

Abstract

Non-toxic aqueous compositions are provided having antibacterial activity. Specifically, the invention provides aqueous alkyl glycoside or saccharide alkyl ester compositions which meet the antimicrobial effectiveness test criteria set forth in USP 31 <51> in preventing growth of specified bacteria and fungi.

1 - 22 . (canceled) 
     
     
         23 . A method of inhibiting microbial growth in an aqueous pharmaceutical composition comprising, admixing:
 a) at least one alkylsaccharide having antibacterial activity, wherein the alkylsaccharide consists of an alkyl chain length from 12 to 14 carbon atoms linked by glycosidic linkage to a maltose;   b) at least one therapeutic peptide, wherein the therapeutic peptide is octreotide or variant thereof; and   c) ethylenediaminetetraacetic acid (EDTA) or a salt thereof.   
     
     
         24 . The method of  claim 23 , wherein the alkylsaccharide is selected from the group consisting of n-Dodecyl-4-O-α-D-glucopyranosyl-β-D-glucopyranoside and n-tetradecyl-4-O-α-D-glucopyranosyl-β-D-glucopyranoside. 
     
     
         25 . The method of  claim 23 , wherein the concentration of the alkylsaccharide is about 0.05% to 0.5% by weight. 
     
     
         26 . The method of  claim 23 , wherein the concentration of alkylsaccharide is about 0.125% to 0.25% by weight. 
     
     
         27 . The method of  claim 23 , wherein the concentration of EDTA is from about 0.01% to 2% by weight. 
     
     
         28 . The method of  claim 23 , wherein the pH is about 7.0 or less. 
     
     
         29 . The method of  claim 23 , wherein the composition is formulated for administration transmucosally, transdermally, optically, or by injection. 
     
     
         30 . The method of  claim 23 , wherein microbial growth is inhibited of  Candida albicans, Aspergillus brasiliensis  ( Aspergillus niger ),  Escherichia coli, Staphylococcus aureus , or  Pseudomonas aeruginosa.